These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 21858048)

  • 21. mRNA therapeutics in cancer immunotherapy.
    Beck JD; Reidenbach D; Salomon N; Sahin U; Türeci Ö; Vormehr M; Kranz LM
    Mol Cancer; 2021 Apr; 20(1):69. PubMed ID: 33858437
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An
    Brown LV; Gaffney EA; Wagg J; Coles MC
    J R Soc Interface; 2018 Mar; 15(140):. PubMed ID: 29540543
    [TBL] [Abstract][Full Text] [Related]  

  • 23. All in the superfamily: presentation of antigen receptors in the context of the major histocompatibility complex.
    Leserman L
    Ann Inst Pasteur Immunol; 1987; 138(1):53-63. PubMed ID: 2953354
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exploiting B-cell Receptor Stereotypy to Design Tailored Immunotherapy in Chronic Lymphocytic Leukemia.
    Rovida A; Maccalli C; Scarfò L; Dellabona P; Stamatopoulos K; Ghia P
    Clin Cancer Res; 2021 Feb; 27(3):729-739. PubMed ID: 33051305
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma.
    Engelhard VH; Obeng RC; Cummings KL; Petroni GR; Ambakhutwala AL; Chianese-Bullock KA; Smith KT; Lulu A; Varhegyi N; Smolkin ME; Myers P; Mahoney KE; Shabanowitz J; Buettner N; Hall EH; Haden K; Cobbold M; Hunt DF; Weiss G; Gaughan E; Slingluff CL
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32385144
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?
    Parmiani G; Castelli C; Dalerba P; Mortarini R; Rivoltini L; Marincola FM; Anichini A
    J Natl Cancer Inst; 2002 Jun; 94(11):805-18. PubMed ID: 12048268
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Specific immunotherapy of cancer in elderly patients.
    Matzku S; Zöller M
    Drugs Aging; 2001; 18(9):639-64. PubMed ID: 11599633
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predicting CD4 T-cell epitopes based on antigen cleavage, MHCII presentation, and TCR recognition.
    Schneidman-Duhovny D; Khuri N; Dong GQ; Winter MB; Shifrut E; Friedman N; Craik CS; Pratt KP; Paz P; Aswad F; Sali A
    PLoS One; 2018; 13(11):e0206654. PubMed ID: 30399156
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peptide-based vaccination and induction of CD8+ T-cell responses against tumor antigens in breast cancer.
    Harao M; Mittendorf EA; Radvanyi LG
    BioDrugs; 2015 Feb; 29(1):15-30. PubMed ID: 25523015
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The present status and future prospects of peptide-based cancer vaccines.
    Hirayama M; Nishimura Y
    Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic cancer vaccines.
    Acres B; Paul S; Haegel-Kronenberger H; Calmels B; Squiban P
    Curr Opin Mol Ther; 2004 Feb; 6(1):40-7. PubMed ID: 15011780
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advances in personalized neoantigen vaccines for cancer immunotherapy.
    Sun C; Xu S
    Biosci Trends; 2020 Nov; 14(5):349-353. PubMed ID: 32908077
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel multi-epitope peptide vaccine against cancer: an in silico approach.
    Nezafat N; Ghasemi Y; Javadi G; Khoshnoud MJ; Omidinia E
    J Theor Biol; 2014 May; 349():121-34. PubMed ID: 24512916
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Composite peptide-based vaccines for cancer immunotherapy (Review).
    Yang J; Zhang Q; Li K; Yin H; Zheng JN
    Int J Mol Med; 2015 Jan; 35(1):17-23. PubMed ID: 25395173
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cancer immunotherapy with lymphocytes genetically engineered with T cell receptors for solid cancers.
    Chen L; Qiao D; Wang J; Tian G; Wang M
    Immunol Lett; 2019 Dec; 216():51-62. PubMed ID: 31597088
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytotoxic T-lymphocyte elicited therapeutic vaccine candidate targeting cancer against MAGE-A11 carcinogenic protein.
    Kumar N; Sood D; Gupta A; Jha NK; Jain P; Chandra R
    Biosci Rep; 2020 Dec; 40(12):. PubMed ID: 33169789
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemical castration of melanoma patients does not increase the frequency of tumor-specific CD4 and CD8 T cells after peptide vaccination.
    Vence LM; Wang C; Pappu H; Anson RE; Patel TA; Miller P; Bassett R; Lizee G; Overwijk WW; Komanduri K; Benjamin C; Alvarado G; Patel SP; Kim K; Papadopoulos NE; Bedikian AY; Homsi J; Hwu WJ; Boyd R; Radvanyi L; Hwu P
    J Immunother; 2013 May; 36(4):276-86. PubMed ID: 23603862
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TLR4- and TRIF-dependent stimulation of B lymphocytes by peptide liposomes enables T cell-independent isotype switch in mice.
    Pihlgren M; Silva AB; Madani R; Giriens V; Waeckerle-Men Y; Fettelschoss A; Hickman DT; López-Deber MP; Ndao DM; Vukicevic M; Buccarello AL; Gafner V; Chuard N; Reis P; Piorkowska K; Pfeifer A; Kündig TM; Muhs A; Johansen P
    Blood; 2013 Jan; 121(1):85-94. PubMed ID: 23144170
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improving T cell responses to modified peptides in tumor vaccines.
    Buhrman JD; Slansky JE
    Immunol Res; 2013 Mar; 55(1-3):34-47. PubMed ID: 22936035
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An In vivo study: Adjuvant activity of poly-n-vinyl-2-pyrrolidone-co-acrylic acid on immune responses against Melanoma synthetic peptide.
    Kızılbey K; Mansuroğlu B; Derman S; Mustafaeva Akdeste Z
    Bioengineered; 2018 Jan; 9(1):134-143. PubMed ID: 28910565
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.